<a href="https://www.fiercebiotech.com/biotech/innovent-fresh-12b-deal-posts-phase-3-win-cldn182-adc" hreflang="en">Innovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC</a>
Innovent Biologics has achieved a phase 3 success with its antibody-drug conjugate IBI343 for treating advanced gastric cancer, enhancing its position in the competitive CLDN18.2 drug market. The drug, partnered with Takeda, is undergoing regulatory review in China following promising results in progression-free survival compared to standard therapies.
Innovent Biologics' phase 3 success with IBI343, partnered with Takeda, highlights the competitive edge in leveraging antibody-drug conjugates (ADCs) targeting CLDN18.2 for gastrointestinal tumors, particularly as it positions them ahead in the race for regulatory approval in China. For someone tracking healthtech and biotech investments, this underscores both the growing interest in ADCs and the strategic partnerships required to accelerate market entry, suggesting that investments in ADC platforms and collaborations could be highly lucrative.